CELMoDs
Jul 25, 2024
CELMoDs – A Worthy Successor to REVLIMID?
Over the years, REVLIMID has become an integral weapon in the cancer therapeutics armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the treatment of adult patients with multiple myeloma, in combination with dexamethasone. As the wise say,...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
